Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02043015|
Recruitment Status : Completed
First Posted : January 23, 2014
Results First Posted : January 17, 2018
Last Update Posted : January 17, 2018
|Condition or disease||Intervention/treatment||Phase|
|HIV||Behavioral: Condom choices Behavioral: Condom-compatible lubricant choices Behavioral: Couples HIV counseling and testing (CVCT) Drug: Pre-exposure prophylaxis with FTC/TDF Other: Staff and provider MSM and LGBT sensitization training Behavioral: HIV Testing and Risk-reduction counseling Behavioral: Linkage to care||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study|
|Actual Study Start Date :||February 2015|
|Actual Primary Completion Date :||October 2016|
|Actual Study Completion Date :||March 2017|
Comprehensive HIV prevention services
A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
Behavioral: Condom choices
Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
Behavioral: Condom-compatible lubricant choices
Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
Behavioral: Couples HIV counseling and testing (CVCT)
Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
Drug: Pre-exposure prophylaxis with FTC/TDF
For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
Other Name: PrEP
Other: Staff and provider MSM and LGBT sensitization training
The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
Behavioral: HIV Testing and Risk-reduction counseling
Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
Behavioral: Linkage to care
Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
- Retention in the Cohort [ Time Frame: 12 months ]The ability of the study to retain participants for full study period was assessed. Retention was measured by the number and percentage of enrolled participants attending study visits through the 12-month study period.
- Use of PrEP [ Time Frame: 4 months ]Uptake of PrEP by study participants was measured as the number and percentage of enrolled participants eligible for PrEP at the baseline and 3-month study visits who choose to initiate PrEP at a visit one month later.
- Number of Participants With New HIV Infection [ Time Frame: 12 months ]Incident HIV infection is measured as the number of seroconversions during follow-up among those who are HIV-uninfected at baseline.
- Condom Use [ Time Frame: Months 3, 6, and 12 ]Condom use is measured as the number of male anal sex partners that the study participant always used condoms with in the prior three or six months, as self-reported reported in the questionnaire at each study visit.
- Lubricant Use [ Time Frame: Months 3, 6, and 12 ]Measured as the number and percentage of participants who used condom-compatible lubricant during their most recent anal sex act, among those who also used a condom at their most recent anal sex act.
- Voluntary Counseling and Testing (VCT) and Couples Voluntary Counseling and Testing (CVCT) Uptake [ Time Frame: 12 months ]VCT and CVCT is measured as the number and percentage of participants who completed VCT in the study period as part of the study visits and the number and percentage of participants who self-reported VCT outside of their study visits. These are compared to the number and percentage of participants who self-reported having VCT in the year prior at baseline. CVCT is measured as the number and percentage of participants who completed a CVCT session as part of the study.
- Number of HIV Tests During Study [ Time Frame: 12 months ]The number of HIV tests per participant administered during the study period.
- Serodiscordant Unprotected Anal Intercourse (UAI) [ Time Frame: Month 3, 6, and 12 ]Measured as any self-reported unprotected anal intercourse in the last three or six months with a partner of opposite or unknown HIV status, as self-reported in the questionnaire at each study visit.
- Acceptability of Post-exposure Prophylaxis (PEP) [ Time Frame: 12 months ]Measured as the number of men who report an eligible exposure who accept and initiate PEP.
- Acceptability of Provider Training [ Time Frame: 12 months ]Measured as the number of providers who accept the training related to MSM-specific healthcare.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02043015
|United States, Georgia|
|Rollins School of Public Health|
|Atlanta, Georgia, United States, 30322|
|United States, Maryland|
|Johns Hopkins School of Public Health|
|Baltimore, Maryland, United States, 21205|
|Desmond Tutu HIV Foundation|
|Cape Town, South Africa|
|Principal Investigator:||Patrick S Sulivan, DVM, PhD||Rollins School of Public Health|
|Principal Investigator:||A.D. McNaghten, PhD, MHSA||Rollins School of Public Health|
|Principal Investigator:||Stefan Baral, MD, MPH||Johns Hopkins Bloomberg School of Public Health|
|Principal Investigator:||Linda-Gail Bekker, MBChB, PhD||Desmond Tutu HIV Centre|
|Principal Investigator:||Rob Stephenson, MSc, PhD||Rollins School of Public Health|
|Principal Investigator:||Chris Beyrer, MD, MPH||Johns Hopkins Bloomberg School of Public Health|